Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological effects of Goal Directed Therapy in surgical patients
2006-004160-32Phase 4Completed
- Sponsor
- Queen Mary University of London
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dopexamine, sponsored by Queen Mary University of London. Primary endpoint: 28-day postoperative complication rate. Started Sep 2006; status: completed.
02
Drugs
dopexamine
Beyond the preview
Go deeper on 2006-004160-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004160-32.